Trials / Completed
CompletedNCT02521649
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
An Open, Dose-ranging, Multicenter Study to Determine the Antibody Response to G17DT and Its Safety and Tolerability in the Treatment of Patients With Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- Not accepted
Summary
An open, dose-ranging, multiple dose, multi-centre study in patients with Stage I-III or Stage IV gastric cancer. Twelve patients in each of 5 treatment groups were to receive three injections at weeks 0, 2 and 6 with provision for a single booster injection in an extension study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | G17DT |
Timeline
- Start date
- 1998-09-01
- Primary completion
- 2001-01-01
- Completion
- 2001-01-01
- First posted
- 2015-08-13
- Last updated
- 2015-08-13
Source: ClinicalTrials.gov record NCT02521649. Inclusion in this directory is not an endorsement.